Abstract
Our understanding of RNA has evolved over the last 20 years from the initial concept that RNA is simply an intermediate in protein synthesis or a structural component maintaining and expressing genetic information. Subsequently, the non-coding RNAs have attracted huge interest and have been developed as therapeutic reagents as well as research tools. An example of RNA-based therapeutic application is the Tetrahymena group I intron-based trans-splicing ribozyme, which cleaves target RNA and trans-ligates an exon tagged at its 3สน end onto the downstream U nucleotide of the targeted RNA. Here, we describe the specific trans-splicing ribozyme that can sense and reprogram human telomerase reverse transcriptase (hTERT)-encoding RNA. This ribozyme converts hTERT RNA to therapeutic transgene herpes simplex virus (HSV) thymidine kinase (tk) and exhibits cytotoxicity to various hTERT-expressing cancer cells. For use in cancer therapy, CMV promoter-driven hTERTRibozyme.HSVtk expression cassette is inserted into adenovirus genome and delivered into either subcutaneous or intraspleenic liver-metastasized xenograft. We present here an evaluation of the inhibitory effects of CMV.hTERTRibozyme.HSVtk on tumor growth.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Puerta-Fernandez, E., Romero-Lopez, C., Barroso-delJesus, A., and Berzal-Herranz, A. (2003) HIV-1 TAR as anchoring site for optimized catalytic RNAs. FEMS Microbiol Rev, 27, 75โ97.
Pavco, P.A., Bouhana, K.S., Gallegos, A.M., Agrawal, A., Blanchard, K.S., Grimm, S.L., Jensen, K.L., Andrews, L.E., Wincott, F.E., Pitot, P.A., Tressler, R.J., Cushman, C., Reynolds, M.A., and Parry, T.J. (2000) Antitumor and antimetastatic activity of ribozymes targeting the messenger RNA of vascular endothelial growth factor receptors. Clin Cancer Res, 6, 2094โ2103.
Bagheri, S. and Kashani-Sabet, M. (2004) Ribozymes in the age of molecular therapeutics. Curr Mol Med, 4, 489โ506.
Lewin, A.S. and Hauswirth, W.W. (2001) Ribozyme gene therapy: applications for molecular medicine. Trends Mol Med, 7, 221โ228.
Been, M.D. and Cech, T.R. (1986) One binding site determines sequence specificity of Tetrahymena pre-rRNA self-splicing, trans-splicing, and RNA enzyme activity. Cell, 47, 207โ216.
Sullenger, B.A. and Cech, T.R. (1994) Ribozyme-mediated repair of defective mRNA by targeted, trans-splicing. Nature, 371, 619โ622.
Jones, J.T., Lee, S.W., and Sullenger, B.A. (1996) Tagging ribozyme reaction sites to follow trans-splicing in mammalian cells. Nat Med, 2, 643โ648.
Lan, N., Howrey, R.P., Lee, S.W., Smith, C.A., and Sullenger, B.A. (1998) Ribozyme-mediated repair of sickle beta-globin mRNAs in erythrocyte precursors. Science, 280, 1593โ1596.
Phylactou, L.A., Darrah, C., and Wood, M.J. (1998) Ribozyme-mediated trans-splicing of a trinucleotide repeat. Nat Genet, 18, 378โ381.
Rogers, C.S., Vanoye, C.G., Sullenger, B.A., and George, A.L., Jr. (2002) Functional repair of a mutant chloride channel using a trans-splicing ribozyme. J Clin Invest, 110, 1783โ1789.
Ryu, K.J., Kim, J.H., and Lee, S.W. (2003) Ribozyme-mediated selective induction of new gene activity in hepatitis C virus internal ribosome entry site-expressing cells by targeted trans-splicing. Mol Ther, 7, 386โ395.
Shin, K.S., Sullenger, B.A., and Lee, S.W. (2004) Ribozyme-mediated induction of apoptosis in human cancer cells by targeted repair of mutant p53 RNA. Mol Ther, 10, 365โ372.
Hong, S.H., Jeong, J.S., Lee, Y.J., Jung, H.I., Cho, K.S., Kim, C.M., Kwon, B.S., Sullenger, B.A., Lee, S.W., and Kim, I.H. (2008) In vivo reprogramming of hTERT by trans-splicing ribozyme to target tumor cells. Mol Ther, 16, 74โ80.
Kwon, B.S., Jung, H.S., Song, M.S., Cho, K.S., Kim, S.C., Kimm, K., Jeong, J.S., Kim, I.H., and Lee, S.W. (2005) Specific regression of human cancer cells by ribozyme-mediated targeted replacement of tumor-specific transcript. Mol Ther, 12, 824โ834.
Jeong, J.S., Lee, S.W., Hong, S.H., Lee, Y.J., Jung, H.I., Cho, K.S., Seo, H.H., Lee, S.J., Park, S., Song, M.S., Kim, C.M., and Kim, I.H. (2008) Antitumor effects of systemically delivered adenovirus harboring trans-splicing ribozyme in intrahepatic colon cancer mouse model. Clin Cancer Res, 14, 281โ290.
Song, M.S., Jeong, J.S., Ban, G., Lee, J.H., Won, Y.S., Cho, K.S., Kim, I.H., and Lee, S.W. (2009) Validation of tissue-specific promoter-driven tumor-targeting trans-splicing ribozyme system as a multifunctional cancer gene therapy device in vivo. Cancer Gene Ther, 16, 113โ125.
Lan, N., Rooney, B.L., Lee, S.W., Howrey, R.P., Smith, C.A., and Sullenger, B.A. (2000) Enhancing RNA repair efficiency by combining trans-splicing ribozymes that recognize different accessible sites on a target RNA. Mol Ther, 2, 245โ255.
Giavazzi, R., Jessup, J.M., Campbell, D.E., Walker, S.M., and Fidler, I.J. (1986) Experimental nude mouse model of human colorectal cancer liver metastases. J Natl Cancer Inst, 77, 1303โ1308.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
ยฉ 2010 Springer Science+Business Media, LLC
About this protocol
Cite this protocol
Lee, SJ., Lee, SW., Jeong, JS., Kim, IH. (2010). In Vivo Reprogramming of Human Telomerase Reverse Transcriptase (hTERT) by Trans-Splicing Ribozyme to Target Tumor Cells. In: Sioud, M. (eds) RNA Therapeutics. Methods in Molecular Biology, vol 629. Humana Press. https://doi.org/10.1007/978-1-60761-657-3_20
Download citation
DOI: https://doi.org/10.1007/978-1-60761-657-3_20
Published:
Publisher Name: Humana Press
Print ISBN: 978-1-60761-656-6
Online ISBN: 978-1-60761-657-3
eBook Packages: Springer Protocols